Skip to main content
. 2016 May 24;6(8):1232–1243. doi: 10.7150/thno.14409

Figure 6.

Figure 6

Post-erlotinib human lung tumor biopsies display increased CRAF and NRAS expression compared to pre-treatment specimens. A. Immunohistochemical staining of phospho-ERK, NRAS and CRAF demonstrating increased CRAF and NRAS expression in post-erlotinib tumor sections compared to paired pre-treatment specimens. B. Schematic representation of targeting the MAPK pathway to overcome both adaptive resistance and acquired resistance to EGFR inhibitors.